This site requires JavaScript to render the code.

Need to know how to enable JavaScript? Go here.

Review our webinar: Clinical Validation of HPV assays on the NeuMoDx Platform

Self-screen’s Chief Scientific Officer dr. Bart Hesselink talks about the clinical validation of QIAGEN’s next generation HPV screening assay on the NeuMoDxTM Molecular Systems ( The NeuMoDxTM 288 and NeuMoDxTM96 Molecular Systems are fully automated continuous random-access analyzers that perform adequately in standardized, high volume cervical cancer HPV screening laboratories. The HPV Test Strip is fully compliant with the International Guidelines for HPV screening assays and has been validated for both physician taken and self-collected specimens and ThinPrep and SurePath collection media.